Gufic BioSciences Ltd (GUFICBIO)
₹378.85
Mkt cap
₹3,627 Cr
P/E ratio
57.40
P/B
5.72
Div yield
0.03%
ROE
9.98%
ROCE
12.20%
EPS (TTM)
₹6.60
Book value
₹66
52W range
274–407
Sector
Healthcare
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
Health check
Constructive
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−6.93% from high₹379
₹274+38.52% from low₹407
Current
₹378.85
Prev close
₹382.40
Day
−0.93%
Price performance
1D
−0.93%
1W
−3.78%
1M
+4.76%
3M
+27.00%
6M
+23.93%
1Y
−1.71%
YTD
+12.42%
Financials
FRevenue, profit & margin
P/E ratio
57.4×
GUFICBIO is 73% above the sector median of 33.3×
GUFICBIO57.4×
Sector median33.3×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 | 231 | 252 | |
| Expenses | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 | 195 | 206 | |
| Operating Profit | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 | 36 | 46 | |
| OPM % | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% | 16% | 18% | |
| Other Income | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | |
| Interest | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | |
| Depreciation | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | |
| Profit before tax | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 | 21 | 28 | |
| Tax % | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% | 26% | 26% | |
| Net Profit | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 | 16 | 21 | |
| EPS in Rs | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 | 1.55 | 2.05 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202672.50%Promoter
Promoters72.50%
FIIs0.42%0.02
DIIs3.83%0.09
Public23.23%0.07
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,862.80 | 35.82 | 4,46,948 | 0.86% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹6,713.50 | 67.94 | 1,78,222 | 0.45% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹4,516.20 | 69.74 | 1,52,849 | 0.84% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,440.10 | 30.56 | 1,16,338 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Dr Reddy's Labs | ₹1,350.50 | 26.86 | 1,12,723 | 0.59% | 221 | −86.14% | 7,546 | −11.51% | 13.64% |
| Zydus Lifesci. | ₹1,101.40 | 20.43 | 1,10,827 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.15% |
| Lupin | ₹2,343.50 | 18.59 | 1,07,152 | 0.51% | 1,469 | +101.49% | 7,475 | +31.89% | 30.32% |
| Gufic BioScience | ₹361.65 | 57.43 | 3,627 | 0.03% | 21 | +158.09% | 252 | +22.94% | 12.17% |
| Median: 157 Co. | ₹408.30 | 33.25 | 1,798 | 0.09% | 12 | +22.34% | 177 | +16.22% | 15.14% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012nseFinancial Year 2012bse
Concall transcripts48
Credit ratings6
Announcements5
Closure of Trading Window 2dAnnouncement under Regulation 30 (LODR)-Newspaper Publication 18 Jun - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 5 Jun - Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Saraswat Co-Operative Bank Limited 2 Jun - Gufic clarifies Saraswat Bank share subscription is for borrower linkage on ₹230 crore facilities, not acquisition.Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Saraswat Co-Operative Bank Limited 2 Jun - Clarifies Saraswat Bank share subscription is share-linkage for ₹230 crore borrowings, not a strategic investment.